Belite Bio logo
Belite Bio
BLTE | NASDAQ
Chart Builder DCF Calculator
$162.56
-$1.79 (-1.09%)
At close: Nov 16, 2026, 4:00 PM ET
$163.00
+$0.44 (+0.27%)
After-hours: Nov 16, 2026, 4:30 PM ET

Belite Bio Company Profile

Company profile explained

Company Profile

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.

Key Executives

Name Position
Yu-Hsin Lin Chairman of the Board of Directors & Chief Executive Officer
Hao-Yuan Chuang Chief Financial Officer & Director
Hendrik Scholl Chief Medical Officer
Kelly Kilpatrick Chief Commercial Officer
Nathan L. Mata Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 30, 2026 4 Filing
Oct 30, 2026 4 Filing
Oct 30, 2026 4 Filing
Oct 19, 2026 6-K Filing
Oct 05, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 08, 2026 6-K Filing
Aug 14, 2026 4 Filing
Aug 14, 2026 4 Filing
View All SEC Filings ➞
Belite Bio
Belite Bio logo
Country United States
IPO Date Apr 29, 2022
Industry Biotechnology
Sector Healthcare
Employees 41
CEO Yu-Hsin Lin

Contact Details

12750 High Bluff Drive San Diego, California 92130 United States

Stock Details

Ticker Symbol BLTE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001889109
CUSIP Number 07782B104
ISIN Number US07782B1044
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.